2012
DOI: 10.1016/s0140-6736(11)61940-5
|View full text |Cite|
|
Sign up to set email alerts
|

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

8
330
0
30

Year Published

2012
2012
2017
2017

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 574 publications
(368 citation statements)
references
References 33 publications
8
330
0
30
Order By: Relevance
“…PETnegative patients received no additional RT. 67 Of the 739 qualified patients with residual disease (≥2.5 cm) after 6 to 8 cycles of BEACOPP, 548 (74%) were PET-negative; 191 patients (26%) were PET-positive and received consolidative RT. The final analysis showed that the prognosis of patients in PR with PET-negative persistent residual disease after chemotherapy was similar to that of those who were in CR as measured by conventional CT (4-year PFS was 92.1%), suggesting that consolidative RT could be omitted in patients with a PET-negative PR.…”
Section: Stage Iii-ivmentioning
confidence: 99%
See 2 more Smart Citations
“…PETnegative patients received no additional RT. 67 Of the 739 qualified patients with residual disease (≥2.5 cm) after 6 to 8 cycles of BEACOPP, 548 (74%) were PET-negative; 191 patients (26%) were PET-positive and received consolidative RT. The final analysis showed that the prognosis of patients in PR with PET-negative persistent residual disease after chemotherapy was similar to that of those who were in CR as measured by conventional CT (4-year PFS was 92.1%), suggesting that consolidative RT could be omitted in patients with a PET-negative PR.…”
Section: Stage Iii-ivmentioning
confidence: 99%
“…58,64,67 The landmark randomized trial by the CALBG showed that ABVD alone or alternating with MOPP was superior to MOPP alone in patients with newly diagnosed advanced HL (stage III-IV). 68 ABVD also was less myelotoxic than MOPP or ABVD alternating with MOPP, and has since been the standard treatment for patients with stage III-IV disease.…”
Section: Stage Iii-ivmentioning
confidence: 99%
See 1 more Smart Citation
“…The randomized GHSG HD15 trial aimed at reducing treatment toxicity without compromising efficacy [16]. Chemotherapy within this trial consisted of eight cycles of BEACOPP escalated , six cycles of BEACOPP escalated or eight cycles of BEACOPP-14, a time-dense variant of the BEACOPP baseline protocol.…”
Section: Treatment Of Advanced Stagesmentioning
confidence: 99%
“…In the broader sense, the use of 18 F-fluorodeoxyglucose (FDG) PET/CT in oncology is a form of theranostics, especially when linked to a decision on therapy. This is especially evident in, for example, modern protocols for the treatment of lymphoma, where the decision on additional treatment with, for example, external beam radiotherapy (EBRT) depends on whether FDG-positive lesions are still present after a number of chemotherapy cycles [22]. In modern EBRT, PET/CT using various tracers such as FDG or 18 F-fluoroethyltyrosine is also a clear diagnostic test which is linked to a specific therapy, as modern radiotherapy approaches use PET/CT for planning the extent of EBRT, as well as to determine where an additional radiation boost needs to be applied in intensity-modulated radiotherapy [23].…”
mentioning
confidence: 99%